Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib and Icotinib in NSCLC with Uncommon EGFR Mutations
NCT06517953Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 24 months. Started Jul 2024; status: recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06517953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517953.